Natural Capsules Limited NATCAPSUQ NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.naturalcapsules.com

Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy-free gelatin, shiny gelatin, sodium lauryl sulfate-free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.

Market & Price

Market Cap

₹168.90 Cr

Current Price

₹162.62

High / Low (52W)

₹276.93 / ₹143.57

Beta

-0.14

Valuation

Stock P/E

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹219.30

Price to Book

0.74

P/S

0.97

EV/EBITDA

-65.99

Dividend Yield

Profitability & Returns

ROCE

2.85%

ROE

ROA

Profit Margin

-11.03%

Op Margin

-17.71%

EPS (Latest Qtr)

₹-6.88

EPS (TTM)

₹-18.51

Balance Sheet & Liquidity

Debt/Equity

0.46

Quick Ratio

Current Ratio

Debt

₹112.11 Cr

Total Assets

₹419.35 Cr

Current Assets

₹129.59 Cr

Working Capital

₹29.59 Cr

Ownership

Promoter Holding

65.52%

Chg in Prom Hold

FII / Inst Holding

0.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹299.17 Cr

Total Revenue (TTM)

₹173.72 Cr

EBITDA

₹-4.53 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹1.04 Cr

Gross Margin

46.27%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

8.12%

Profit 5Y

-64.60%

Revenue (YoY)

-13.90%

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Earnings shrank at -64.6% CAGR over 5 years.
Trading 41.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NATCAPSUQ Natural Capsules Limited NSEPHARMA	162.62	-	₹168.90 Cr	-	2.85%	-	8.12%	-64.60%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	43.83 Cr	39.92 Cr	45.20 Cr	45.80 Cr	37.75 Cr
Cost of Revenue	-	22.29 Cr	26.33 Cr	23.57 Cr	24.32 Cr	18.97 Cr
Gross Profit	-	21.54 Cr	13.59 Cr	21.63 Cr	21.48 Cr	18.77 Cr
Operating Expenses	-	19.61 Cr	10.74 Cr	25.52 Cr	26.66 Cr	25.46 Cr
Operating Income	-	1.93 Cr	2.85 Cr	-3.89 Cr	-5.17 Cr	-6.69 Cr
EBITDA	-	4.38 Cr	4.69 Cr	67.77 L	-72.31 L	-1.88 Cr
Interest Expense	-	1.54 Cr	1.64 Cr	2.53 Cr	2.68 Cr	2.85 Cr
Pretax Income	-	50.21 L	89.13 L	-6.06 Cr	-7.70 Cr	-9.08 Cr
Tax Provision	-	39.65 L	37.05 L	-48.39 L	-70.59 L	-1.97 Cr
Net Income	-	10.57 L	52.07 L	-5.58 Cr	-6.99 Cr	-7.12 Cr
Diluted EPS	-0.60	0.10	-	-5.40	-6.76	-6.88

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	129.88 Cr	164.72 Cr	151.29 Cr	164.15 Cr
Cost of Revenue	61.49 Cr	81.91 Cr	82.36 Cr	88.43 Cr
Gross Profit	68.38 Cr	82.81 Cr	68.93 Cr	75.73 Cr
Operating Expenses	45.42 Cr	55.57 Cr	58.61 Cr	66.70 Cr
Operating Income	22.97 Cr	27.24 Cr	10.32 Cr	9.03 Cr
EBITDA	26.39 Cr	35.61 Cr	21.85 Cr	18.22 Cr
Interest Expense	1.96 Cr	3.41 Cr	5.13 Cr	6.31 Cr
Pretax Income	19.39 Cr	24.99 Cr	8.05 Cr	2.79 Cr
Tax Provision	5.47 Cr	6.55 Cr	2.50 Cr	2.17 Cr
Net Income	13.91 Cr	18.45 Cr	5.55 Cr	61.74 L
Diluted EPS	19.84	19.86	5.97	0.63

Compounded Sales Growth

5 Years:	8.12%
1 Year:	-13.90%

Compounded Profit Growth

5 Years:	-64.60%
1 Year:	-

Stock Price Performance

1 Year:	-29.35%
6 Months:	-12.38%
3 Months:	+2.92%
1 Month:	+4.32%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	164.28 Cr	288.76 Cr	376.53 Cr	419.35 Cr
Current Assets	75.58 Cr	101.51 Cr	123.77 Cr	129.59 Cr
Cash & Equivalents	1.40 Cr	1.27 Cr	1.95 Cr	66.29 L
Inventory	4.58 Cr	8.85 Cr	19.04 Cr	25.46 Cr
Receivables	26.30 Cr	52.13 Cr	54.47 Cr	62.24 Cr
Total Liabilities	81.30 Cr	140.51 Cr	147.72 Cr	162.19 Cr
Current Liabilities	44.77 Cr	66.94 Cr	76.49 Cr	99.99 Cr
Long Term Debt	34.25 Cr	70.39 Cr	67.93 Cr	56.40 Cr
Total Debt	52.78 Cr	96.79 Cr	109.01 Cr	105.19 Cr
Total Equity	82.98 Cr	123.23 Cr	203.80 Cr	232.94 Cr
Shares Outstanding	93.49 L	92.76 L	93.49 L	1.04 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	-52.18 L	17.22 Cr	-8.35 Cr	26.75 Cr
Investing Cash Flow	-45.88 Cr	-104.63 Cr	-72.59 Cr	-44.48 Cr
Financing Cash Flow	47.70 Cr	87.49 Cr	81.72 Cr	16.17 Cr
Capital Expenditure	-46.08 Cr	-105.89 Cr	-71.63 Cr	-44.63 Cr
Free Cash Flow	-46.60 Cr	-88.67 Cr	-79.98 Cr	-17.88 Cr
Net Change in Cash	1.30 Cr	7.92 L	77.70 L	-1.57 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	52.7%	50.3%	45.6%	46.1%
Operating Margin %	17.7%	16.5%	6.8%	5.5%
Net Margin %	10.7%	11.2%	3.7%	0.4%
ROE %	16.8%	15.0%	2.7%	0.3%
ROCE %	19.2%	12.3%	3.4%	2.8%

Shareholding Pattern

Insiders

65.52%

Institutions

0.00%

Public Float

0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NATCAPSUQ

No recent headlines available.

NATCAPSUQ · Healthcare